AMEX · Drug Manufacturers - Specialty & Generic

YCBD (YCBD) Stock

$0.47 -3.68% AMEX: YCBD Healthcare

Valuation

MetricValue
Price$0.47
Market Cap$4.94M
P/E Ratio-0.69
P/B Ratio1.12
P/S Ratio0.41
EPS (TTM)$-1.09
52-Week High$2.56
52-Week Low$0.47
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-28.57%
ROA-20.00%
ROCE-28.57%
Gross Margin-10.53%
Operating Margin-10.53%
Net Margin-15.54%
Debt/Equity0.04
Current Ratio2.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$44.0M$35.0M$24.0M$19.0M$19.0M
Operating Profit$-20.0M$-17.0M$-9.0M$-3.0M$-2.0M
Net Profit$-23.0M$-70.0M$-23.0M$-4.0M$-2.0M
EPS$-19.16$-55.80$-13.32$-1.79$-1.09
Op Margin-44.1%-48.9%-38.4%-16.4%-11.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$125.0M$41.0M$16.0M$11.0M$10.0M
Total Liabilities$22.0M$9.0M$7.0M$9.0M$3.0M
Cash$26.0M$7.0M$2.0M$2.0M$2.0M
Borrowings$6.0M$5.0M$4.0M$1.0M$778.0M

Latest News

cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina PR Newswire · Jul 14, 2026 cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation PR Newswire · Jul 9, 2026 cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination PR Newswire · Jul 7, 2026 Oasis Launches Hemp-Derived Mixer PR Newswire · Jul 1, 2026 cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products PR Newswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-15.0M$-4.0M$0$-1.0M
Investing Cash Flow$-5.0M$-1.0M$0$-1.0M$0
Financing Cash Flow$-31.0M$0$0$0$0
Net Cash Flow$12.0M$-20.0M$-5.0M$1.0M$0
Free Cash Flow$-16.0M$-16.0M$-5.0M$-1.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-2120.10%
Quick Ratio1.59
Interest Coverage—
Return 1Y-33.82%
Return 3Y-94.37%
Return 5Y-99.93%

Ownership

Insiders Held10.68%
Institutions Held8.96%
Institutions Float Held10.03%
Institutional HolderSharesReport Date
Worth Venture Partners, Llc184,7962026-03-31
UBS Group AG164,6432026-03-31
CSS LLC137,6212026-03-31
Xtx Topco Ltd92,0492026-03-31
Chapin Davis, Inc.81,2502026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BFRI $1.17 -4.88% -0.90 $14.98M 0.00%
CDIO $1.62 +4.52% -0.53 $3.35M 0.00%
EVOKEvoke Pharma, Inc. $11.00 +0.00% -6.96 $18.95M 0.00%
FLGCFlora Growth Corp. $7.79 -32.14% -0.54 $4.23M 0.00%
GBSGBS Inc. $0.47 -1.58% -0.18 $433577 0.00%

About YCBD

YCBD is led by CEO T. Ronan Kennedy, publicly traded since 2017.

YCBD stock trades at $0.47 with a market capitalization of $4.94M. The stock is valued at a price-to-earnings (P/E) ratio of -0.69, price-to-book of 1.12, price-to-sales of 0.41. Over the past 52 weeks the stock has ranged between $0.47 and $2.56, and currently trades 81.6% below its 52-week high.

On profitability, YCBD generates a return on equity (ROE) of -28.57%, return on capital employed of -28.57%, an operating margin of -10.53%, a net profit margin of -15.54%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides